Protagenic Therapeutics will host a webinar with Dr. Maurizio Fava for its lead molecule PT00114 on Tuesday, July 13 at 10:00 a.m.ET



NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) – Protagenic Therapeutics, Inc. (Nasdaq: PTIX), a biopharmaceutical company focused on developing therapies to treat stress-related neurological disorders, today announced that it will host a Key Opinion Leader (KOL) webinar focused on PT00114 for Stress Regulation in Patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10 a.m. ET.

The webinar will include a presentation by Dr. Maurizio Fava, Chief Psychiatrist of the Department of Psychiatry at Massachusetts General Hospital (MGH), who is the Principal Investigator of the upcoming Phase 1 / 2a clinical trial of Protagenic. The Protagenic management team will also provide an overview of the clinical development program of PT00114, scientifically known as the C-terminal Content Associated Peptide (TCAP), a natural peptide responsible for regulating the stress response. in the brain.

Dr Maurizio Fava is an international leader in the field of depression. In addition to being the Chief Psychiatrist in the Department of Psychiatry at Massachusetts General Hospital, he is also Director of the Clinical Research Division of the Mass General Research Institute, Associate Dean of Clinical and Translational Research and Professor of Slater Family Psychiatry at Harvard Medical School. In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (“CTNI”), the first academic contract research organization (“CRO”) specializing in the planning and coordination of clinical trials. multicentric in psychiatry. . He has authored or co-authored over 800 original articles published in international medical journals, edited eight books and published over 50 chapters and over 600 abstracts. Dr Fava obtained his medical degree from the University of Padua.

To register for the webinar, contact James Carbonara at Hayden IR, office: (646) -755-7412, or [email protected].

About Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a preclinical biopharmaceutical company working to develop first-class neuroactive peptides in human therapeutics to treat several stress-related disorders. For more information, visit http://www.protagenic.com.

Forward-looking statements

This press release contains forward-looking statements made in accordance with the safe harbor provisions of federal securities laws, including statements regarding Protagenic Therapeutics product candidates and preclinical development and clinical trial plans and activities. Forward-looking statements include words such as “expects”, “anticipates”, “intention”, “plans”, “may”, “believes”, “believes” and similar expressions. These forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially. These risks and uncertainties include, among others, our ability to raise additional capital to meet our liquidity needs on acceptable terms, if at all, including the additional capital that will be required to complete preclinical tests and possible trials. clinics of our product. candidates; our ability to successfully research, develop and market our product candidates; uncertainties inherent in preclinical and clinical trials; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any senior management or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors described in the Risk Factors section of our most recent annual report on Form 10-K filed with the Securities and Exchange Commission. Protagenic Therapeutics cautions investors not to place significant reliance on any forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Protagenic assumes no obligation to update or revise any statements, except to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Analyst Contact:
Alexander K. Arrow, MD, CFA
Financial director
213-260-4342
[email protected]

Media contact:
James carbonara
Hayden IR
(646) -755-7412
[email protected]


Previous US internet giants strike back at Hong Kong's Doxxing law
Next Esri announces ArcGIS Online 2021 competition winners

No Comment

Leave a reply

Your email address will not be published.